Urologic device regulatory approvals have declined since the 1990s in traditionally dominant subspecialties. While growth is emerging in underrepresented areas such as URPS and neurourology, prolonged approval timelines within these subspecialties may impede progress. Regulatory reform and industry support may help revitalize innovation in urologic technology.
Duggan et al. (Thu,) studied this question.